Merged drug development firms close on $2.3 million Series B funding round
Madison, Wis. , June 5, 2008 — Mithridion, Inc., and Cognitive Pharmaceuticals, Ltd., both private drug discovery and development companies focusing on drugs for Alzheimer’s disease and other serious Central Nervous System (CNS) disorders, announce they have merged. Mithridion, Inc. is the surviving entity, and will maintain its headquarters and preclinical drug research laboratories in
The merged company also announces the closing of a Series B funding round, which will provide the company with $2.3 million in staged financing. Venture Investors (
The company expects soon to commence clinical trials of its first drug candidate, MCD-386, a drug candidate developed with technology invented in the laboratories of Professor William S. Messer, Jr., Ph.D., of the College of Pharmacy, University of Toledo. MCD-386 is aimed at improving brain function and stopping or slowing down the disease processes that cause brain cell death in Alzheimer’s disease. The merged company has an exclusive worldwide license from the
Trevor M. Twose, Ph.D., continues as the Chief Executive Officer of Mithridion. Paul M. Weiss, Ph.D., a Managing Director of Venture Investors, continues as a board director of Mithridion. Three of Cognitive Pharmaceuticals’ senior executives will play continuing roles in the merged company. Wayne P. Hoss, Ph.D., CEO of Cognitive Pharmaceuticals, will join the board of directors of Mithridion, and will direct the
“The merger and new funding is a big step towards the company realizing its goal of developing greatly-needed drugs for Alzheimer’s disease,” said Twose. “It brings together an exciting clinical-stage drug candidate, a technology expected to provide additional drug candidates, an experienced management team, a strong drug development team, and new funding,” he added.
“The merger with Mithridion, coupled with the Series B financing led by Venture Investors, is an outstanding opportunity to move MCD-386 into the clinic in the short term, and reap the many benefits of our combined operations in the longer term”, said Hoss.
”We believe that MCD-386 represents an exciting opportunity to address significant unmet medical need in the treatment of Alzheimer’s disease. The team at Cognitive has developed a promising molecule that is ready to enter clinical trials. Mithridion has state-of-the-art infrastructure for working on CNS drug development, and is led by a very experienced pharmaceutical industry executive. Together, Cognitive and Mithridion combine the complementary skills needed to develop and manage a pipeline of products to address CNS disorders”, commented Weiss.
“We are pleased to continue our investment with a strengthened team working in a healthcare area of critical importance,” said Bob Wood, speaking on behalf of Wisconsin Investment Partners, an angel investing group active in supporting early stage business growth in the
Mithridion is based at the
Venture Investors LLC is a venture capital firm with over $200 million under management. The firm invests in seed and early-stage life science and technology companies in the